Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 15/20 | 0.86 |
| ▸ | MMP1 | P03956 | 3/20 | 0.86 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.86 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.86 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.86 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.86 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.86 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.86 |
| ▸ | MMP2 | P08253 | 1/20 | 0.86 |
| ▸ | MMP7 | P09237 | 1/20 | 0.86 |
| ▸ | MMP10 | P09238 | 1/20 | 0.86 |
| ▸ | MMP9 | P14780 | 1/20 | 0.86 |
| ▸ | MMP13 | P45452 | 1/20 | 0.86 |
| ▸ | MMP14 | P50281 | 1/20 | 0.86 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.86 |
| ▸ | MMP3 | P08254 | 2/20 | 0.53 |
| ▸ | NPY1R | P25929 | 1/20 | 0.49 |
| ▸ | SRC | P12931 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13934576 | 1.00 | APP (0.86) | APPMMP1PSEN1PSEN2APH1B | |
| SCHEMBL6166785 | 1.00 | APP (0.86) | APPMMP1PSEN1PSEN2APH1B | |
| SCHEMBL311595 | 0.97 | APP (0.86) | APPMMP1PSEN1PSEN2APH1B | |
| SCHEMBL6859558 | 0.97 | APP (0.86) | APPMMP1PSEN1PSEN2APH1B | |
| SCHEMBL6094611 | 0.97 | APP (0.86) | APPMMP1PSEN1PSEN2APH1B | |
| SCHEMBL13934568 | 0.97 | APP (0.86) | APPMMP1PSEN1PSEN2APH1B | |
| SCHEMBL311596 | 0.97 | APP (0.86) | APPMMP1PSEN1PSEN2APH1B | |
| SCHEMBL14375081 | 0.93 | APP (0.87) | APPMMP1PSEN1PSEN2APH1B | |
| SCHEMBL4498899 | 0.93 | APP (0.87) | APPMMP1PSEN1PSEN2APH1B | |
| SCHEMBL13934636 | 0.93 | APP (0.87) | APPMMP1PSEN1PSEN2APH1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050245501-A1 | Succinoylamino lactams as inhibitors of A-beta protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-11-03 | — | — | US | claimed |
| EP-1102752-B1 | SUCCINOYLAMINO LACTAMS AS INHIBITORS OF A BETA PROTEIN PRODUCTION | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2005-10-19 | — | — | EP | claimed |
| US-6794381-B1 | BETA -PEPTIDE INHIBITOR PREVENTS NEUROLOGICAL DEPOSITS OF AMYLOID PRECURSOR PROTEIN; ALZHEIMER'S DISEASE AND DOWN'S SYNDROME TREATMENT | BRISTOL-MYERS SQUIBB COMPANY | 2004-09-21 | — | — | US | claimed |
| US-20030134841-A1 | Succinoylamino lactams as inhibitors of A-beta protein production | OLSON RICHARD E (US) | 2003-07-17 | — | — | US | claimed |
| US-20110105485-A1 | Alpha-(N-Sulfonamido)Acetamide Derivatives as Beta-Amyloid Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-05-05 | — | — | US | disclosed |
| US-20110059940-A1 | 2-Aryl Glycinamide Derivatives | BRISTOL- MYERS SQUIBB COMPANY | 2011-03-10 | — | — | US | disclosed |
| US-7786122-B2 | α-(N-sulfonamido)acetamide derivatives as β-amyloid inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-08-31 | — | — | US | disclosed |
| US-7786122-B2 | α-(N-sulfonamido)acetamide derivatives as β-amyloid inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-08-31 | — | — | US | disclosed |
| WO-2009137657-A1 | 2-ARYL GLYCINAMIDE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-11-12 | — | — | WO | disclosed |
| EP-1465861-B1 | ALPHA-(N-SULPHONAMIDO)ACETAMIDE DERIVATIVES AS BETA-AMYLOID INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2009-05-06 | — | — | EP | disclosed |
| US-7507815-B2 | Succinoylamino lactams as inhibitors of a-β protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2009-03-24 | — | — | US | disclosed |
| US-7507815-B2 | Succinoylamino lactams as inhibitors of a-β protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2009-03-24 | — | — | US | disclosed |
| WO-2005054180-A1 | ANTIAMYLOID PHENYLSULFONAMIDES: N-CYCLOALKYLCARBOXAMIDES DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-06-16 | — | — | WO | disclosed |
| US-6878363-B2 | Use of small molecule radioligands to discover inhibitors of amyloid-beta peptide production and for diagnostic imaging | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-04-12 | — | — | US | disclosed |
| US-20050019255-A1 | Use of small molecule radioligands to discover inhibitors of amyloid-beta peptide production and for diagnostic imaging | ZACZEK ROBERT (US) | 2005-01-27 | — | — | US | disclosed |
| US-6794381-B1 | BETA -PEPTIDE INHIBITOR PREVENTS NEUROLOGICAL DEPOSITS OF AMYLOID PRECURSOR PROTEIN; ALZHEIMER'S DISEASE AND DOWN'S SYNDROME TREATMENT | BRISTOL-MYERS SQUIBB COMPANY | 2004-09-21 | — | — | US | disclosed |
| US-6737038-B1 | CONTACTING POTENTIAL INHIBITOR AND TAGGED INHIBITOR OF BETA-AMYLOID PRODUCTION WITH MACROMOLECULE CONTAINING BINDING SITE SPECIFIC FOR TAGGED INHIBITOR, SEPARATING BOUND INHIBITOR, DETERMINING INHIBITORY CONCENTRATION | BRISTOL-MYERS SQUIBB COMPANY | 2004-05-18 | — | — | US | disclosed |
| US-20030134841-A1 | Succinoylamino lactams as inhibitors of A-beta protein production | OLSON RICHARD E (US) | 2003-07-17 | — | — | US | disclosed |
| US-20020159947-A1 | Use of small molecule radioligands to discover inhibitors of amyloid-beta peptide production and for diagnostic imaging | LANTHEUS MEDICAL IMAGING, INC. | 2002-10-31 | — | — | US | disclosed |
| US-6331408-B1 | CONTACTING A POTENTIAL INHIBITOR OF BETA-AMYLOID PRODUCTION AND TAGGED INHIBITOR OF BETA-AMYLOID PRODUCTION WITH AT MACROMOLECULE INVOLVED IN PROCESSING OF AMYLOID PRECURSOR PROTEIN; SEPARATING TAGGED INHIBITOR, DETERMINING | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2001-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020159947-A1 | Use of small molecule radioligands to discover inhibitors of amyloid-beta peptide production and for diagnostic imaging | APP, BACE1, BACE2 | APP 1/4885MMP1 3487/4885PSEN1 5/4885 |
| US-20110059940-A1 | 2-Aryl Glycinamide Derivatives | IAPP, APP, BACE1 | APP 2/4885MMP1 3155/4885PSEN1 8/4885 |
| US-20050245501-A1 | Succinoylamino lactams as inhibitors of A-beta protein production | BACE1, APH1A, APP | APP 3/4885MMP1 3143/4885PSEN1 7/4885 |
| US-20050019255-A1 | Use of small molecule radioligands to discover inhibitors of amyloid-beta peptide production and for diagnostic imaging | APP, BACE1, BACE2 | APP 1/4885MMP1 3703/4885PSEN1 4/4885 |
| US-20110105485-A1 | Alpha-(N-Sulfonamido)Acetamide Derivatives as Beta-Amyloid Inhibitors | APP, APBA1, BACE1 | APP 1/4885MMP1 2651/4885PSEN1 5/4885 |
| US-20030134841-A1 | Succinoylamino lactams as inhibitors of A-beta protein production | APH1A, BACE1, APP | APP 3/4885MMP1 2986/4885PSEN1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.